DK2401270T3 - Pyrazolderivater anvendt som CCR4-receptorantagonister. - Google Patents

Pyrazolderivater anvendt som CCR4-receptorantagonister.

Info

Publication number
DK2401270T3
DK2401270T3 DK10705594.9T DK10705594T DK2401270T3 DK 2401270 T3 DK2401270 T3 DK 2401270T3 DK 10705594 T DK10705594 T DK 10705594T DK 2401270 T3 DK2401270 T3 DK 2401270T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
pyrazole derivatives
derivatives used
ccr4 receptor
ccr4
Prior art date
Application number
DK10705594.9T
Other languages
English (en)
Inventor
Heather Hobbs
Simon Teanby Hodgson
Yannick Maurice Lacroix
Deborah Needham
Nigel James Parr
Panayiotis Alexandrou Procopiou
Timothy John Ritchie
Michael David Woodrow
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK2401270T3 publication Critical patent/DK2401270T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK10705594.9T 2009-02-26 2010-02-24 Pyrazolderivater anvendt som CCR4-receptorantagonister. DK2401270T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15570209P 2009-02-26 2009-02-26
PCT/EP2010/052307 WO2010097395A1 (en) 2009-02-26 2010-02-24 Pyrazole derivatives used as ccr4 receptor antagonists

Publications (1)

Publication Number Publication Date
DK2401270T3 true DK2401270T3 (da) 2014-01-13

Family

ID=42110309

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10705594.9T DK2401270T3 (da) 2009-02-26 2010-02-24 Pyrazolderivater anvendt som CCR4-receptorantagonister.

Country Status (30)

Country Link
US (3) US8304446B2 (da)
EP (1) EP2401270B1 (da)
JP (1) JP5520969B2 (da)
KR (1) KR20110128896A (da)
CN (1) CN102388039B (da)
AR (1) AR075594A1 (da)
AU (2) AU2010217629A1 (da)
BR (1) BRPI1013396A2 (da)
CA (1) CA2753337A1 (da)
CL (1) CL2011002103A1 (da)
CO (1) CO6420342A2 (da)
DK (1) DK2401270T3 (da)
DO (1) DOP2011000272A (da)
EA (1) EA021740B1 (da)
ES (1) ES2439773T3 (da)
HR (1) HRP20131174T1 (da)
IL (1) IL214655A0 (da)
MA (1) MA33132B1 (da)
MX (1) MX2011008972A (da)
NZ (1) NZ594641A (da)
PE (1) PE20120307A1 (da)
PL (1) PL2401270T3 (da)
PT (1) PT2401270E (da)
RS (1) RS53133B (da)
SG (1) SG173768A1 (da)
SI (1) SI2401270T1 (da)
SM (1) SMT201400001B (da)
TW (1) TW201041879A (da)
UY (1) UY32464A (da)
WO (1) WO2010097395A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2575816B2 (ja) 1988-06-13 1997-01-29 田中貴金属工業株式会社 粉末等の送り方法
ES2529648T3 (es) 2007-08-31 2015-02-24 Eisai R&D Management Co., Ltd. Compuesto policíclico
EP2401277A1 (en) 2009-02-26 2012-01-04 Eisai R&D Management Co., Ltd. Salt of tetrahydrotriazolopyridine derivative and crystal thereof
TW201035101A (en) 2009-02-26 2010-10-01 Eisai R&D Man Co Ltd Nitrogen-containing fused heterocyclic compound
US8729260B2 (en) * 2010-05-19 2014-05-20 Savior Lifetec Corporation Process for the preparation of carbapenem using cabapenem intermediates and recovery of cabapenem
WO2012025473A1 (en) * 2010-08-24 2012-03-01 Glaxo Group Limited Cc.chemokine receptor 4 antagonists
WO2015127125A1 (en) * 2014-02-20 2015-08-27 Cornell University Compounds and methods for inhibiting fascin
PL3490565T3 (pl) 2016-07-29 2022-09-26 Rapt Therapeutics, Inc. Pochodne azetydyny jako modulatory receptora chemokinowego i ich zastosowanie
WO2018049271A1 (en) 2016-09-09 2018-03-15 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JOP20190192A1 (ar) * 2017-03-01 2019-08-08 Glaxosmithkline Ip No 2 Ltd مشتقات بيرازول بوصفها مثبطات برومودومين
WO2018187509A1 (en) 2017-04-04 2018-10-11 Flx Bio, Inc. Heterocyclic compounds as chemokine receptor modulators
JP7090639B2 (ja) * 2017-04-11 2022-06-24 サンシャイン・レイク・ファーマ・カンパニー・リミテッド フッ素置換されたインダゾール化合物及びその使用
RU2020118594A (ru) 2017-11-06 2021-12-09 Рапт Терапьютикс, Инк. Противораковые агенты
CN110028501B (zh) * 2018-01-12 2022-02-22 迈德欣国际有限公司 化合物及其制备方法和用途
AU2019212478C1 (en) 2018-01-26 2023-11-16 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
CN113893220A (zh) * 2020-07-07 2022-01-07 迈德欣国际有限公司 鼻粘膜给药剂型和其应用
CN119585256A (zh) 2022-04-06 2025-03-07 拉普特医疗公司 趋化因子受体调节剂及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2848554A1 (fr) * 2002-12-12 2004-06-18 Aventis Pharma Sa Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
PL376789A1 (pl) * 2002-12-12 2006-01-09 Aventis Pharma S.A. Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer

Also Published As

Publication number Publication date
SMT201400001B (it) 2014-03-07
TW201041879A (en) 2010-12-01
EA201190142A1 (ru) 2012-05-30
NZ594641A (en) 2013-03-28
DOP2011000272A (es) 2011-12-31
JP2012518673A (ja) 2012-08-16
EP2401270A1 (en) 2012-01-04
US8507543B2 (en) 2013-08-13
AU2010217629A1 (en) 2011-09-15
KR20110128896A (ko) 2011-11-30
PL2401270T3 (pl) 2014-03-31
CN102388039B (zh) 2015-07-15
US20100216860A1 (en) 2010-08-26
PT2401270E (pt) 2014-01-20
EP2401270B1 (en) 2013-10-16
AU2016203684A1 (en) 2016-06-23
CL2011002103A1 (es) 2012-02-24
US8304446B2 (en) 2012-11-06
US8357716B2 (en) 2013-01-22
RS53133B (sr) 2014-06-30
HK1159621A1 (en) 2012-08-03
CA2753337A1 (en) 2010-09-02
MX2011008972A (es) 2011-12-14
SG173768A1 (en) 2011-09-29
IL214655A0 (en) 2011-09-27
JP5520969B2 (ja) 2014-06-11
PE20120307A1 (es) 2012-04-04
BRPI1013396A2 (pt) 2016-03-29
CO6420342A2 (es) 2012-04-16
ES2439773T3 (es) 2014-01-24
CN102388039A (zh) 2012-03-21
HRP20131174T1 (hr) 2014-01-17
UY32464A (es) 2010-09-30
WO2010097395A1 (en) 2010-09-02
US20120015932A1 (en) 2012-01-19
EA021740B1 (ru) 2015-08-31
MA33132B1 (fr) 2012-03-01
US20130030031A1 (en) 2013-01-31
SI2401270T1 (sl) 2014-01-31
AR075594A1 (es) 2011-04-20

Similar Documents

Publication Publication Date Title
LTPA2020528I1 (lt) Benzimidazolo dariniai
DK2401269T3 (da) Indolderivater som crth2-receptorantagonister
DK2445903T3 (da) 1,3-Disubstituerede imidazolidin-2-on-derivater som CYP17-inhibitorer
IL214655A0 (en) Pyrazole derivatives used as ccr4 receptor antagonists
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
DK2501704T3 (da) Spiropiperidinforbindelser som oral-1-receptorantagonister
DK2501703T3 (da) Spiropiperidinforbindelser som orl-1-receptorantagonister
DK2374797T3 (da) Benzazepinderivater til anvendelse som vasopressinantagonister
DK2004654T3 (da) Pyrazolopyrimidin derivater til anvendelse som kinase antagonister
DK2308877T3 (da) Imidazopyridin-2-on-derivater
ECSP12011999A (es) Derivados benzamida sustituidos
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
DK2176220T3 (da) Pyrrolidin-2-on-derivater som androgenreceptormodulatorer.
DK2401256T3 (da) Forbindelser som bradykinin-B1-antagonister.
BRPI0914301A2 (pt) derivados de pirimidin-4-ona substituída
DK2069310T3 (da) Sulfonylpyrazolin-1-carboxamidin-derivater som 5-HT6-antagonister
DK2089367T3 (da) Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister
EP2155712A4 (en) 3- (IMIDAZOLYL) pyrazolo [3,4-B] PYRIDINE
DK2275414T3 (da) Cyclopentylacrylamidderivat
DK2799428T3 (da) Glucagon-antagonister
IL207846A0 (en) Arylsulfonyl pyrazoline carboxaidine derivatives as 5-ht6 antagonists
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
BRPI0907963A2 (pt) Derivados de indazola
BR112012016923A2 (pt) Derivados de pirazol
BRPI0906714A2 (pt) Derivados de oxazepinopirimidona heteroarilamida substituídos.